ShareValue scores for NECLIFE.NSE: Valuation 74, Quality 25, Growth 32, Health 46.

Nectar Lifesciences Limited logo

NECLIFE.NSE
NSE

Nectar Lifesciences Limited

₹10.53(-0.75%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

12% to 29%
Valuation
74
Undervalued
Price vs Value
Quality
25
Weak
Business Strength
Growth
32
Weak
Revenue & Earnings
Health
46
Moderate
Financial Stability
Momentum
40
Neutral
Price Trend

Company Details

About

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026